1. Study involved 66 patients with hidradenitis suppurativa receiving GLP-1 RAs.
2. 54% achieved at least a 1-point reduction in HS-PGA score.
3. Mean HS-PGA scores decreased from 3 to 2.
4. Most patients received semaglutide; median age was 46, 58% were women.
5. Follow-up lasted 19 months; 60% reported fewer flares.
6. Study design was retrospective with some limitations acknowledged.
7. Recommendations for future randomized clinical trials.

Source: JAMA Dermatology